Investing in Malaria in Pregnancy in Sub-Saharan Africa: Saving Women’s and Children’s Lives

What is the danger of malaria in pregnancy (MiP)?
Each year, MiP is responsible for:

Pregnancies → 20% of stillbirths in sub-Saharan Africa¹

Newborns → 100,000 newborn deaths globally²
11% of all newborn deaths in sub-Saharan Africa³

Mothers → 10,000 maternal deaths globally³

IPTp-SP works! It provides significant benefit by reducing the incidence of:⁴,⁵

- 29% Low birthweight
- 38% Severe maternal anaemia
- 31% Neonatal mortality

APPROXIMATELY 94,000 newborn lives saved through MiP interventions between 2009 and 2012

The World Health Organization Recommends

- Routine administration of IPTp-SP
- Consistent use of ITNs before, during and after pregnancy
- Effective diagnosis and treatment
- Administration of low-dose folic acid during ANC

What can be done?

- Aim for scale-up and full coverage of WHO lifesaving interventions.
- Promote early and regular ANC attendance.
- Preserve SP efficacy by avoiding its use for treating clinical cases of malaria.
- Reserve SP stocks for IPTp at ANC clinics.

What about pregnant women living with HIV?

- Pregnant women living with HIV on cotrimoxazole should not receive SP because administration of both drugs together could cause harm.
- It is especially important that pregnant women living with HIV sleep under an ITN and access prompt and effective diagnosis and treatment if they have symptoms of malaria.

IPTp-SP = intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine
ANC = antenatal care
ITN = insecticide-treated net
WHO = World Health Organization
MiP = malaria in pregnancy

¹ Each year, MiP is responsible for 20% of stillbirths in sub-Saharan Africa.
² 100,000 newborn deaths globally each year.
³ 11% of all newborn deaths in sub-Saharan Africa.
⁴ 31% reduction in neonatal mortality.
⁵ 38% reduction in severe maternal anaemia.

Roll Back Malaria
USAID
UNICEF
The Global Fund
Bill & Melinda Gates Foundation
MMV
Maternal Health Task Force
Medicines for Malaria Venture
Key Message 1:
MiP is a serious global public health issue.

1. Malaria infection in pregnancy carries serious risks for pregnant women, foetuses and newborns, including anaemia, severe malaria, spontaneous abortion, stillbirth, prematurity, neonatal mortality and low birthweight.6
2. As malaria prevalence in a country declines, adverse consequences will likely increase in pregnant women because of delayed acquisition of immunity due to reduced exposure.7
3. Addressing MiP is key to malaria elimination efforts since the placenta can be a reservoir of infection.
4. Pregnant women co-infected with malaria and HIV are more vulnerable to the severe outcomes of both diseases.

Key Message 2:
Investing in MiP programs makes a difference in the lives of mothers and newborns.

1. IPTp-SP is cost-effective and prevents adverse consequences of malaria, i.e., placental infection, clinical malaria, maternal anaemia, foetal anaemia, low birthweight and mortality.4,5
   a. Severe maternal anaemia reduced by 38%.
   b. Low birthweight is reduced by 29%.
   c. Neonatal mortality is reduced by 31%.
2. MiP prevention can avert newborn deaths.
   a. About 300,000 deaths could have been averted if IPTp-SP and ITN coverage had increased to 80% from 2009 to 2012.
3. IPTp-SP continues to protect against low birthweight even in areas of low malaria transmission.9
4. IPTp will continue to be important until malaria has been eradicated.

Key Message 3:
Comprehensive MiP programming is needed and ensures full coverage of interventions.

1. WHO recommends these lifesaving interventions:
   a. In areas of moderate to high transmission of malaria, IPTp at every ANC visit, starting as early as possible in the 2nd trimester, with doses at least a month apart.
   b. ITN use before, during and after pregnancy.
   c. Parasitological testing and treatment according to national guidelines.
2. Scale-up of efforts is needed because coverage of effective tools is low:
   a. 40% of eligible pregnant women received two or more doses of IPTp-SP and 17% received three or more doses.10
   b. ITN use among pregnant women is 38%.11
   c. Effective case management in pregnancy is largely unknown.12
3. Investment in health systems strengthening, including effective monitoring and evaluation, is critical to scale up and sustain gains over time for MiP.
4. The Roll Back Malaria Global Call to Action focusing on IPTp-SP scale-up includes information on effective interventions and strategies for increasing coverage.13

---

3. Guyatt and Snow. 2001. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-saharan Africa. AJTMH. 64(1,2):S: 36-44.